CapsoVision, Inc
CV Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2024–FY2025
Last close · Oct 23, 2026
$6.99
2.8%
Revenue
Total sales reported in the income statement.
$13.6M
15.3%
vs prior year
Operating margin
Operating income as a share of revenue.
−188.3%
18.8 pts
Net income
Profit after all expenses, interest and tax.
−$25.3M
Free cash flow
Cash from operations minus capital spending.
−$23.0M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
$349M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
2.2x
On $3.18 EPS (TTM)
What CapsoVision, Inc does
No business description yet.
- Legal name
- CapsoVision, Inc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Accession · CIK
- 0001378325-26-000010
0001378325
Revenue and margins
CapsoVision, Inc had $13.6M of revenue in fiscal 2025, up 15.3% on the year before.
FY24
Revenue $11.8M
FY25
Revenue $13.6M
Q1 '24
Revenue —
Q2 '24
Revenue $2.8M
Q3 '24
Revenue $3.0M
Q4 '24
Revenue $3.5M
Q1 '25
Revenue $2.8M
Q2 '25
Revenue $3.3M
Q3 '25
Revenue $3.5M
Q4 '25
Revenue $3.9M
Q1 '26
Revenue $2.8M
Q2 '26
Revenue $3.6M
FY24
Gross 54.2%
Operating −169.4%
Net −169.3%
FCF −172.2%
FY25
Gross 52.9%
Operating −188.3%
Net −186.8%
FCF −169.4%
Gross
Operating
Net
FCF
Q1 '24
Gross —
Operating —
Net —
FCF —
Q2 '24
Gross 56.0%
Operating −185.4%
Net −185.2%
FCF —
Q3 '24
Gross 55.9%
Operating −195.7%
Net −195.3%
FCF −238.0%
Q4 '24
Gross 50.2%
Operating −134.2%
Net −134.4%
FCF −156.4%
Q1 '25
Gross 53.7%
Operating −193.4%
Net −193.1%
FCF −180.6%
Q2 '25
Gross 54.6%
Operating −140.3%
Net −139.5%
FCF −137.4%
Q3 '25
Gross 54.1%
Operating −226.7%
Net −223.9%
FCF −160.5%
Q4 '25
Gross 49.9%
Operating −190.5%
Net −188.7%
FCF −196.4%
Q1 '26
Gross 47.6%
Operating −254.0%
Net −251.9%
FCF −219.0%
Q2 '26
Gross 51.4%
Operating −208.1%
Net −205.4%
FCF −230.7%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY24
Net income −$19.9M
FY25
Net income −$25.3M
Q1 '24
Net income −$4.2M
Q2 '24
Net income −$5.3M
Q3 '24
Net income −$5.8M
Q4 '24
Net income −$4.6M
Q1 '25
Net income −$5.4M
Q2 '25
Net income −$4.6M
Q3 '25
Net income −$7.9M
Q4 '25
Net income −$7.4M
Q1 '26
Net income −$7.0M
Q2 '26
Net income −$7.5M
FY24
Diluted EPS −$9.85
FY25
Diluted EPS −$1.03
Q1 '24
Diluted EPS —
Q2 '24
Diluted EPS −$2.58
Q3 '24
Diluted EPS −$2.79
Q4 '24
Diluted EPS —
Q1 '25
Diluted EPS −$2.49
Q2 '25
Diluted EPS −$2.02
Q3 '25
Diluted EPS −$0.17
Q4 '25
Diluted EPS $3.65
Q1 '26
Diluted EPS −$0.15
Q2 '26
Diluted EPS −$0.15
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY24
Return on capital —
Return on equity —
Return on assets −118.4%
FY25
Return on capital —
Return on equity —
Return on assets −144.8%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$23.0M in fiscal 2025, −169.4% of revenue. Cash from operations minus capital spending.
FY24
Free cash flow −$20.2M
FY25
Free cash flow −$23.0M
Q1 '24
Free cash flow —
Q2 '24
Free cash flow —
Q3 '24
Free cash flow −$7.1M
Q4 '24
Free cash flow −$5.4M
Q1 '25
Free cash flow −$5.0M
Q2 '25
Free cash flow −$4.6M
Q3 '25
Free cash flow −$5.7M
Q4 '25
Free cash flow −$7.7M
Q1 '26
Free cash flow −$6.1M
Q2 '26
Free cash flow −$8.4M
FY24
Cash from operations −$20.1M
Capital spending $0.2M
FY25
Cash from operations −$22.9M
Capital spending $0.1M
Cash from operations
Capital spending
Q1 '24
Cash from operations —
Capital spending —
Q2 '24
Cash from operations —
Capital spending —
Q3 '24
Cash from operations −$7.1M
Capital spending $0.0M
Q4 '24
Cash from operations −$5.4M
Capital spending $0.0M
Q1 '25
Cash from operations −$5.0M
Capital spending $0.0M
Q2 '25
Cash from operations −$4.5M
Capital spending $0.0M
Q3 '25
Cash from operations −$5.7M
Capital spending $0.0M
Q4 '25
Cash from operations −$7.7M
Capital spending $0.0M
Q1 '26
Cash from operations −$6.1M
Capital spending $0.0M
Q2 '26
Cash from operations −$8.4M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
CapsoVision, Inc returned — to shareholders in fiscal 2025. The diluted share count rose 1,115.6%.
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.02B
Balance sheet
Cash, debt and the ratios that show how comfortably CapsoVision, Inc can carry it.
FY24
Cash —
Debt —
FY25
Cash —
Debt —
Cash
Debt
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Current ratio | 8.2x | 3.8x |
| Quick ratio | 6.8x | 3.1x |
| Total assets | $16.8M | $18.2M |
| Total liabilities | $2.7M | $4.9M |
| Shareholders' equity | −$130M | $13.3M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✕ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | ✕ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 2 / 8 |
| Accruals ratio | 1.1% | −14.0% |
| Altman Z'' | −78.75 | −30.12 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $11.8M | $13.6M |
| Gross profit | $6.4M | $7.2M |
| Research and development | $15.1M | $18.3M |
| Operating income | −$19.9M | −$25.5M |
| Pretax income | −$19.9M | −$25.3M |
| Income tax | $0.0M | $0.0M |
| Net income | −$19.9M | −$25.3M |
| Net income to common | −$19.9M | −$25.3M |
| Diluted EPS | −$9.85 | −$1.03 |
| Diluted shares | 0.00B | 0.02B |
| Cash flow | ||
| Cash from operations | −$20.1M | −$22.9M |
| Capital expenditure | $0.2M | $0.1M |
| Free cash flow | −$20.2M | −$23.0M |
| Depreciation and amortization | $0.2M | $0.2M |
| Stock-based compensation | $0.2M | $0.8M |
| Balance sheet | ||
| Current assets | $14.8M | $16.7M |
| Current liabilities | $1.8M | $4.4M |
| Inventory | $2.6M | $3.0M |
| Property and equipment, net | $0.7M | $0.6M |
| Total assets | $16.8M | $18.2M |
| Total liabilities | $2.7M | $4.9M |
| Preferred stock | — | $0.0M |
| Shareholders' equity | −$130M | $13.3M |
| Margins | ||
| Gross margin | 54.2% | 52.9% |
| Operating margin | −169.4% | −188.3% |
| EBITDA margin | −167.7% | −186.7% |
| Net margin | −169.3% | −186.8% |
| FCF margin | −172.2% | −169.4% |
| Returns | ||
| Return on capital employed | −132.8% | −185.7% |
| Return on assets | −118.4% | −144.8% |
| Return on tangible equity | — | −190.9% |
| Growth | ||
| Revenue growth | — | 15.3% |
| Share count change | — | 1,115.6% |
| Financial health | ||
| Current ratio | 8.2x | 3.8x |
| Quick ratio | 6.8x | 3.1x |
| Capital allocation | ||
| Capex / revenue | 1.3% | 0.7% |
| Stock comp / revenue | 1.3% | 6.1% |
| Quality scores | ||
| Piotroski F-score | — | 2.0 |
| Altman Z'' | −78.8 | −30.1 |
| Accruals ratio | 1.1% | −14.0% |
Source: SEC EDGAR XBRL filings (CIK 0001378325). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.